What the research found

A landmark 2017 trial (TRUST) randomised over 770 adults aged 65+ with mildly elevated TSH and normal free T4 to either levothyroxine or placebo for a year. Using a validated symptom questionnaire, researchers found no meaningful difference between the treated and untreated groups across fatigue, tiredness, or other thyroid-related quality-of-life measures. TSH levels did drop as expected in the treatment group, but this biochemical change didn't translate to symptom relief.

The source raises an important caveat: the study enrolled participants with an average baseline TSH around 6 mIU/L, meaning roughly half fell into the 4.6–6 range. Population-level data (NHANES) suggests TSH values in this lower range may actually sit within normal variation rather than representing true disease.

Why it matters for you

If you're tracking TSH as part of your health protocol and seeing values between 4–10 with normal free T4, you're in a diagnostic grey zone where clinical evidence offers limited guidance. The TRUST data suggests starting levothyroxine at this threshold won't reliably improve fatigue or cognitive symptoms—at least in older adults. This matters because it reframes the question: a mildly elevated TSH alone may not be your problem, even if you feel tired.

This doesn't mean your fatigue is unrelated to thyroid function, but it does mean other variables deserve investigation. Sleep quality, training load, caloric deficit, iron or B12 status, and cortisol patterns all drive fatigue and are more readily modifiable than initiating hormone replacement for borderline labs. If your TSH is 5 but your free T4, free T3, and thyroid antibodies are normal, chasing TSH downward with medication may not help you feel better.

Caveats

• Study population was older adults (65+); findings may not generalise to younger, more metabolically active individuals
• Intention-to-treat analysis preserves randomisation but may dilute treatment effect if dropouts weren't balanced
• ~50% of enrolled participants may not have met strict subclinical hypothyroidism criteria, weakening the homogeneity of the treatment group
• No data on whether symptom improvement occurred with higher TSH suppression targets or alternative formulations (e.g. combination T4/T3)
• Single-year follow-up; long-term cardiovascular or bone outcomes weren't the focus